Abstract:Glycogen Synthase Kinase 3 (GSK-3) is a member of cellular kinase with various functions, such as glucose regulation, cellular differentiation, neuronal function and cell apoptosis. It has been proved as an important therapeutic target in type 2 diabetes mellitus and Alzheimer's disease. To better understand their structure–activity relationships and mechanism of action, an integrated computational study, including three dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD), was performed on 79 (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine GSK-3 inhibitors. In this paper, we constructed 3D-QSAR using comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) method. The results showed that the CoMFA model (q 2 = 0.743, r2 = 0.980) and the CoMSIA model (q2 = 0.813, r2 = 0.976) had stable and reliable predictive ability. The electrostatic and H-bond donor fields play important roles in the models. The contour maps of the model visually showed the relationship between the activity of compounds and their three-dimensional structure. Molecular docking was used to identify the key amino acid residues at the active site of GSK-3 and explore its binding mode with ligands. Based on 3D-QSAR models, contour maps and the binding feature between GSK-3 and inhibitor, we designed 10 novel compounds with good potential activity and ADME/T profile. Molecular dynamics simulation results validated that Ile62, Val70 and Lys85 located in the active site play a key role for GSK-3 complexed with inhibitors. These results might provide important information for designing GSK-3 inhibitors with high activity.

Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.

Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors

Design, Synthesis, and Biological Evaluation of Novel 7-Azaindolyl-heteroaryl-maleimides As Potent and Selective Glycogen Synthase Kinase-3 Beta (Gsk-3 Beta) Inhibitors

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

Design, Synthesis and Evaluation of 7-Azaindazolyl-indolyl-maleimides As Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitors

3-(7-Azaindolyl)-4-arylmaleimides As Potent, Selective Inhibitors of Glycogen Synthase Kinase-3.

Synthesis and Biological Evaluation of 3-Benzisoxazolyl-4-indolylmaleimides As Potent, Selective Inhibitors of Glycogen Synthase Kinase-3β

Design, Synthesis, and Evaluation of 3‐aryl‐4‐pyrrolyl‐maleimides As Glycogen Synthase Kinase‐3β Inhibitors

Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3 beta

Design, synthesis and biological evaluation of thieno[3,2- c ]pyrazol-urea derivatives as potent glycogen synthase kinase 3β inhibitors based on the DFG-out conformation

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Synthesis and Biological Evaluation of Novel 4,5-Bisindolyl-1,2,4-triazol-3-ones As Glycogen Synthase Kinase-3Β Inhibitors and Neuroprotective Agents.

ChemInform Abstract: Design, Synthesis, and Evaluation of 3-Aryl-4-pyrrolylmaleimides as Glycogen Synthase Kinase-3β Inhibitors.

Synthesis and Biological Evaluation of 3-([1,2,4]Triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides As Potent, Selective GSK-3β Inhibitors and Neuroprotective Agents.

Design, Synthesis and Biological Evaluation of Benzothiazepinones (btzs) As Novel Non-Atp Competitive Inhibitors of Glycogen Synthase Kinase-3Β (Gsk-3Β).

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.

Biological Evaluation and Energetic Analyses of Novel GSK‐3β Inhibitors

Synthesis and Evaluation of 3-Anilino-quinoxalinones As Glycogen Phosphorylase Inhibitors.

Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5‐diamino‐n‐substituted Benzamide Derivatives As Novel GSK‐3β Small Molecule Inhibitors